Pregnant Women's RSV vaccine shields newborns, Real-World study shows
NCT ID NCT07249320
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 17 times
Summary
This study checks how well the ABRYSVO vaccine works when given during pregnancy to protect babies from RSV, a common respiratory virus. Researchers will compare nearly 40,000 infants born to vaccinated and unvaccinated mothers, tracking infections and hospitalizations up to 24 months after birth. The goal is to provide real-world evidence to guide vaccine policies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.